Precision covalent chemistry: Advances in selectivity-driven covalent drug design over the past five years.
Covalent inhibitors bind tightly and persistently to protein targets via covalent links with nucleophilic amino acids, yet unintended covalent modification of irrelevant proteins creates major safety risks and restricts their clinical use. To tackle this issue, researchers have shifted from reactivity-centered design to selectivity-prioritized engineering, a core trend in this field over the last five years. This review summarizes five synergistic tactics to boost covalent inhibitor selectivity. First, strengthening noncovalent binding affinity accurately positions reactive warheads for target residues and lowers off-target interactions. Second, redesigned warheads - new electrophiles for non-cysteine sites and reversible covalent groups with adjustable binding duration - broaden druggable proteins and separate target and off-target binding via kinetic differences. Third, leveraging distinct nucleophilic microenvironments (isoform-specific amino acid variations, allosteric cavities, mutation-generated residues) enhances target-specific recognition. Fourth, structure-based tuning of warhead spatial shapes controls covalent reaction efficiency and selectivity. Fifth, prodrugs deliver active inhibitors locally at disease sites with temporal and spatial precision. Collectively, these innovations validate kinact/Ki as a unified rule balancing efficacy and selectivity. With advancing proteome profiling, computational warhead modeling and conditional electrophile chemistry, covalent inhibitors will tackle hard-to-drug targets with safety comparable to noncovalent medicines.